HER2-Positive Breast Cancer | Expert Second Opinion: Investigators Discuss Available Clinical Research in the Care of Patients with Challenging Cases of HER2-Positive Breast Cancer

published 2 weeks ago by Dr Neil Love

Featuring perspectives from Drs Erika Hamilton, Ian Krop, and Joyce O’Shaughnessy, including the following topics: Introduction (0:00) Role of Immunotherapy in HER2-Positive Metastatic Breast Cancer (mBC) (1:34) Case: A woman in her mid-50s with ER-positive, HER2-positive mBC enrolled on a clinical trial of nivolumab/ipilimumab — Reshma Mahtani, DO (1:50) Management of HER2-Positive mBC (9:17) Case: A woman in her early 30s with ER-positive, HER2-positive mBC — Ann Partridge, MD, MPH (13:57) Case: A woman in her early 70s with HER2-positive mBC — Dr Mahtani (17:39) Case: A woman in her late 50s with ER-negative, HER2-positive mBC — Ruth O’Regan, MD (21:11) Case: A woman in her early 50s with ER-positive, HER2-positive mBC — Dr Partridge (27:20) Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer (39:22) Case: A woman in her mid-40s with 5-cm ER-positive, HER2-positive localized breast cancer — Dr Mahtani (44:05) Case: A woman in her early 50s with 4.5-mm ER-positive, HER2-positive breast cancer — Dr O’Regan (49:24) CME information and select publications

more episodes from Research To Practice | Oncology Videos